Return to TA187 Overview

Infliximab and adalimumab for the treatment of Crohn's disease [TA187]

Measuring the use of this guidance

Recommendation: 1.1

Infliximab and adalimumab, within their licensed indications, are recommended as treatment options for adults with severe active Crohn's disease (see 1.6) whose disease has not responded to conventional therapy (including immunosuppressive and/or corticosteroid treatments), or who are intolerant of or have contraindications to conventional therapy. Infliximab or adalimumab should be given as a planned course of treatment until treatment failure (including the need for surgery), or until 12 months after the start of treatment, whichever is shorter. People should then have their disease reassessed (see 1.4) to determine whether ongoing treatment is still clinically appropriate.

What was measured: Proportion of adult patients on biological therapy who were appropriately prescribed anti-TNFα in compliance with NICE technology appraisal 187 for the treatment of Crohn's disease.
Data collection end: March 2014
45%
Number that met the criteria: 1035 / 2282
Data collection end: February 2016
46%
Number that met the criteria: 430 / 927
Area covered: National
Source: Royal College of Physicians. National Clinical Audit of Biological therapies: UK Inflammatory Bowel Disease Audit.

What was measured: Adult patients treated with biological therapy in line with whole recommendation.
Data collection end: February 2014
54%
Number that met the criteria: 552 / 1028
Area covered: National
Source: Royal College of Physicians. National Clinical Audit of Biological therapies: UK Inflammatory Bowel Disease Audit.


Recommendation: 1.5

Infliximab, within its licensed indication, is recommended for the treatment of people aged 6–17 years with severe active Crohn's disease whose disease has not responded to conventional therapy (including corticosteroids, immunomodulators and primary nutrition therapy), or who are intolerant of or have contraindications to conventional therapy. The need to continue treatment should be reviewed at least every 12 months.

What was measured: Proportion of paediatric patients on biological therapy who were appropriately prescribed anti-TNFα in compliance with NICE technology appraisal 187 for the treatment of Crohn's disease.
Data collection end: March 2014
14%
Number that met the criteria: 47 / 337
Data collection end: February 2016
20%
Number that met the criteria: 14 / 71
Area covered: National
Source: Royal College of Physicians. National Clinical Audit of Biological therapies: UK Inflammatory Bowel Disease Audit.

What was measured: Paediatric patients treated with biological therapy in line with whole recommendation.
Data collection end: February 2014
12%
Number that met the criteria: 25 / 201
Area covered: National
Source: Royal College of Physicians. National Clinical Audit of Biological therapies: UK Inflammatory Bowel Disease Audit.



 Return to TA187 Overview